These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24515438)

  • 1. Genetic characterization of the role of the Cip/Kip family of proteins as cyclin-dependent kinase inhibitors and assembly factors.
    Cerqueira A; Martín A; Symonds CE; Odajima J; Dubus P; Barbacid M; Santamaría D
    Mol Cell Biol; 2014 Apr; 34(8):1452-9. PubMed ID: 24515438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
    Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
    Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of mice without Cip/Kip CDK inhibitors.
    Tateishi Y; Matsumoto A; Kanie T; Hara E; Nakayama K; Nakayama KI
    Biochem Biophys Res Commun; 2012 Oct; 427(2):285-92. PubMed ID: 23000166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of the cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip1) by phosphorylation directed by the cyclin encoded by Murine Herpesvirus 68.
    Yarmishyn A; Child ES; Elphick LM; Mann DJ
    Exp Cell Res; 2008 Jan; 314(1):204-12. PubMed ID: 17997402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.
    Coats S; Whyte P; Fero ML; Lacy S; Chung G; Randel E; Firpo E; Roberts JM
    Curr Biol; 1999 Feb; 9(4):163-73. PubMed ID: 10074425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
    Chen WJ; Chang CY; Lin JK
    Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
    Tanner FC; Boehm M; Akyürek LM; San H; Yang ZY; Tashiro J; Nabel GJ; Nabel EG
    Circulation; 2000 May; 101(17):2022-5. PubMed ID: 10790340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK inhibitors, p21(Cip1) and p27(Kip1), participate in cell cycle exit of mammalian cardiomyocytes.
    Tane S; Ikenishi A; Okayama H; Iwamoto N; Nakayama KI; Takeuchi T
    Biochem Biophys Res Commun; 2014 Jan; 443(3):1105-9. PubMed ID: 24380855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes.
    Bagui TK; Mohapatra S; Haura E; Pledger WJ
    Mol Cell Biol; 2003 Oct; 23(20):7285-90. PubMed ID: 14517297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
    Reynisdóttir I; Polyak K; Iavarone A; Massagué J
    Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1).
    Martín A; Odajima J; Hunt SL; Dubus P; Ortega S; Malumbres M; Barbacid M
    Cancer Cell; 2005 Jun; 7(6):591-8. PubMed ID: 15950907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p27kip1 Regulates cdk2 activity in the proliferating zone of the mouse intestinal epithelium: potential role in neoplasia.
    Smartt HJ; Guilmeau S; Nasser SV; Nicholas C; Bancroft L; Simpson SA; Yeh N; Yang W; Mariadason JM; Koff A; Augenlicht LH
    Gastroenterology; 2007 Jul; 133(1):232-43. PubMed ID: 17631145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of cyclin D3-cdk4 complexes in fibroblasts expressing and lacking p27(kip1) and p21(cip1).
    Bagui TK; Jackson RJ; Agrawal D; Pledger WJ
    Mol Cell Biol; 2000 Dec; 20(23):8748-57. PubMed ID: 11073976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
    McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
    Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest.
    Green SL; Freiberg RA; Giaccia AJ
    Mol Cell Biol; 2001 Feb; 21(4):1196-206. PubMed ID: 11158306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New functional activities for the p21 family of CDK inhibitors.
    LaBaer J; Garrett MD; Stevenson LF; Slingerland JM; Sandhu C; Chou HS; Fattaey A; Harlow E
    Genes Dev; 1997 Apr; 11(7):847-62. PubMed ID: 9106657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.
    Croucher DR; Rickwood D; Tactacan CM; Musgrove EA; Daly RJ
    Mol Cell Biol; 2010 Nov; 30(21):5057-70. PubMed ID: 20805359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1).
    Greeve MA; Allan RK; Harvey JM; Bentel JM
    J Mol Endocrinol; 2004 Jun; 32(3):793-810. PubMed ID: 15171713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors.
    Lu Z; Hunter T
    Cell Cycle; 2010 Jun; 9(12):2342-52. PubMed ID: 20519948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1).
    Sugimoto M; Martin N; Wilks DP; Tamai K; Huot TJ; Pantoja C; Okumura K; Serrano M; Hara E
    Oncogene; 2002 Nov; 21(53):8067-74. PubMed ID: 12444543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.